EMR
77
-2
NWS
79
-4
EMN
50
-2
GOOGL
59
-8
LNC
45
-4
IFF
53
2
DGX
48
-3
TXN
49
-6
DRI
56
2
PCG
99
2
KO
44
2
XOM
51
3
FOX
57
-3
RSG
77
4
OMC
64
-2
CMI
67
4
C
62
-3
COF
63
-4
WHR
70
4
LEN
52
2
EMR
77
-2
NWS
79
-4
EMN
50
-2
GOOGL
59
-8
LNC
45
-4
IFF
53
2
DGX
48
-3
TXN
49
-6
DRI
56
2
PCG
99
2
KO
44
2
XOM
51
3
FOX
57
-3
RSG
77
4
OMC
64
-2
CMI
67
4
C
62
-3
COF
63
-4
WHR
70
4
LEN
52
2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.
Buy
66

KROS
Keros Therapeutics

Last Price:
62.02
Seasonality Move:
23.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's IRS Hands Massive 'Victory Gift' To 401K Owners

Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.

Keros Therapeutics Price Quote

$62.02
-1.05 (-1.66%)
(Updated: November 14, 2024 at 12:40 PM ET)

Keros Therapeutics Key Stats

Buy
66
Keros Therapeutics (KROS) is a Buy
Day range:
$62.07 - $65.93
52-week range:
$27.31 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3,471.76
P/B ratio:
4.93%
Volume:
329.2K
Avg. volume:
335.7K
1-year change:
110.3%
Market cap:
$2.6B
Revenue:
$151K
EPS:
$-5.21

How Much Does Keros Therapeutics Make?

Is Keros Therapeutics Growing As A Company?

  • What Is Keros Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 47.5%
  • What Is Keros Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$140.3M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $385.5M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.2M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -44.6%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -40.96%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -44.6%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Scholar Rock Holding Corp (SRRK)

Keros Therapeutics Dividend Yield

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -10.52%
Revenue: 4750% 0%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 90.69
Upside from Last Price: 43.8%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    50.1M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.4K KROS shares are owned by insiders